Get the Stockscreener App
26.72
3.15%
-0.87
Metsera Inc stock is traded at $26.72, with a volume of 919.71K.
It is down -3.15% in the last 24 hours and up +14.68% over the past month.
Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions. The Company has developed and is implementing proprietary methods and platform technologies to advance a broad, scalable, and combinable portfolio of injectable and oral NuSH analog peptides with the potential to address not only the limitations of approved therapies but also many of the anticipated limitations of next-generation therapies in development. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization half-life extending platform.
See More
Previous Close:
$27.59
Open:
$27.2
24h Volume:
919.71K
Relative Volume:
0.98
Market Cap:
$2.81B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-2.12%
1M Performance:
+14.68%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$25.47
$27.41
1-Week Range:
$25.47
$29.78
52-Week Range:
$12.30
$32.81
Metsera Inc Stock (MTSR) Company Profile
Name
Metsera Inc
Sector
Industry
Phone
(212) 784-6595
Address
3 WORLD TRADE CENTER, NEW YORK
Compare MTSR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MTSR
Metsera Inc
|
26.72 | 2.87B | 0 | 0 | 0 | 0.00 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Metsera Inc Stock (MTSR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-25 | Initiated | BofA Securities | Buy |
| Feb-25-25 | Initiated | Evercore ISI | Outperform |
| Feb-25-25 | Initiated | Guggenheim | Buy |
Metsera Inc Stock (MTSR) Latest News
Metsera (NASDAQ:MTSR) Trading Down 6.9% – Here’s What Happened - Defense World
Cantor Fitzgerald maintains overweight on Metsera shares By Investing.com - Investing.com India
Cantor Fitzgerald maintains overweight on Metsera shares - Investing.com
Viking among notable gainers as Pfizer raises deal prospects - MSN
Two new option listings and two option delistings on May 22nd - TipRanks
Metsera Inc (NASDAQ: MTSR) Shares Rose Recently, But Trouble Could Still Be Around The Corner. - Stocksregister
Transcript : Metsera, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 02 - marketscreener.com
Decoding Metsera Inc (MTSR): A Strategic SWOT Insight - GuruFocus
Metsera's Q1 Net Loss Narrows - marketscreener.com
Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress - The Manila Times
Metsera, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Earnings Flash (MTSR) Metsera Posts Q1 Net Loss $1.03 a Share, vs. FactSet Est of $0.85 Loss - marketscreener.com
Metsera: A Must-Add To Your Watchlist Thanks To GLP-1 Obesity Promise (NASDAQ:MTSR) - Seeking Alpha
Metsera to Present at Bank of America 2025 Global Healthcare Conference - The Manila Times
Metsera Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Metsera Rings the Opening Bell - Nasdaq
Metsera Inc’s Market Journey: Closing Weak at 22.74, Down -5.17 - DWinneX
MTSR Shares Experience Surge in Value - knoxdaily.com
Nothing is Better Than Metsera Inc (MTSR) stock at the moment - Sete News
Viking stock rises as Pfizer ups deal prospects (VKTX:NASDAQ) - Seeking Alpha
Metsera Inc. appoints new director and legal officer By Investing.com - Investing.com India
Metsera Inc. appoints new director and legal officer - Investing.com
A Guide To The Risks Of Investing In Metsera Inc (MTSR) - knoxdaily.com
Metric Analysis: Metsera Inc (MTSR)’s Key Ratios in the Limelight - DWinneX
A Closer Look at Metsera Inc (MTSR) Stock Gains - investchronicle.com
Metsera Inc (MTSR) stock analysis: A simple moving average approach - uspostnews.com
Metsera, Inc. Appoints New Board Member and Legal Officer - TipRanks
Metsera (NASDAQ:MTSR) Shares Gap Up – Time to Buy? - Defense World
Now Is The Time To Build A Position In Metsera Inc (NASDAQ:MTSR) - Marketing Sentinel
Metsera Inc [MTSR] Director makes an insider purchase of 2,222,222 shares worth 40.0 million. - knoxdaily.com
The Psychology of Metsera Inc Inc. (MTSR) Price Performance: Understanding Market Sentiment - investchronicle.com
Taking the lead: Metsera Inc (MTSR) - Sete News
Financial Metrics Exploration: Understanding Metsera Inc (MTSR) Through Ratios - DWinneX
How did Metsera Inc (MTSR) fare last session? - uspostnews.com
MetaVia’s ‘Safe’ Obesity Drug Resonates With Analysts, But Not Investors - insights.citeline.com
Lilly stock up rallying Structure and Metsera (GPCR:NASDAQ) - Seeking Alpha
Viking, Structure, Metsera on a tear as Pfizer drops obesity pill - MSN
Viking stock on a tear after Pfizer setback (VKTX:NASDAQ) - Seeking Alpha
Is it possible to buy Metsera Inc(MTSR) shares at a good price now? - uspostnews.com
Q1 IPOs Rise From Q4, But Unstable Markets Could Slow New Offerings - insights.citeline.com
Metsera plunges 44% after InvestingPro’s overvaluation warning By Investing.com - Investing.com South Africa
Exclusive: Metsera CEO on what it takes to build an obesity biotech in 2025 - Endpoints News
Metsera sees cash runway into 2027 - TipRanks
Metsera reports Q4 EPS ($3.52) vs. (94c) last year - TipRanks
Are Metsera Inc’shares a good deal? - US Post News
Metsera Inc Stock (MTSR) Financials Data
There is no financial data for Metsera Inc (MTSR). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Metsera Inc Stock (MTSR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BERNS PAUL L | Director |
Feb 03 '25 |
Buy |
18.00 |
789,998 |
14,219,964 |
8,313,680 |
| ARCH Venture Partners XII, LLC | 10% Owner |
Feb 03 '25 |
Buy |
18.00 |
2,222,222 |
39,999,996 |
18,503,128 |
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):